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Pulmonary Illness Related to E-Cigarette Use
To the Editor: We have closely followed recent 
publications (including the letters by Maddock et al. 
[Oct. 10 issue]1 and Butt et al. [Oct. 31 issue]2) on 
e-cigarette, or vaping, product use–associated lung 
injury (EVALI), particularly the role of bronchos-
copy in the diagnostic workup of this condition. 
It has not yet been reported how severely “rou-
tine” flexible bronchoscopy and bronchoalveolar 
lavage (BAL) affect pulmonary function in these 
patients, resulting in a highly challenging peri-
operative course.
We reviewed records for nine of the first pa-
tients with EVALI identified at Children’s Hospital 
of Wisconsin and included in the original case 
series described by Layden et al. (published Sep-
tember 6, 2019, at NEJM.org).3 Preoperatively, most 
patients had only moderate oxygen requirements 
(Table 1). Intraoperatively and postoperatively, all 
patients showed substantial airway reactivity, with 
severe coughing spells and prolonged desatura-
tion. Four patients remained intubated. The se-
verity of airway reactivity was disproportionate to 
the preoperative status and higher than what is 
generally anticipated.
We wish to highlight these risks and advocate 
limiting diagnostic bronchoscopy and BAL to set-
tings where postoperative ventilation is readily 
available. In select patients, we now defer bron-
choscopy and BAL when their preoperative status 
is tenuous or clinical findings are strongly sugges-
tive of EVALI.
Christina D. Diaz, M.D. 
Brian J. Carroll, M.D. 
Ali Hemyari, M.D.
Medical College of Wisconsin 
Milwaukee, WI
No potential conflict of interest relevant to this letter was re-
ported.
This letter was published on November 20, 2019, at NEJM.org.
1. Maddock SD, Cirulis MM, Callahan SJ, et al. Pulmonary 
lipid-laden macrophages and vaping. N Engl J Med 2019; 381: 
1488-9.
2. Butt YM, Smith ML, Tazelaar HD, et al. Pathology of vaping-
associated lung injury. N Engl J Med 2019; 381: 1780-1.
3. Layden JE, Ghinai I, Pray I, et al. Pulmonary illness related 
to e-cigarette use in Illinois and Wisconsin — preliminary report. 
N Engl J Med. DOI: 10.1056/NEJMoa1911614.
DOI: 10.1056/NEJMc1915111
To the Editor: We welcome the report from 
Layden et al. investigating this worrisome outbreak 
of an inflammatory respiratory syndrome with 
multiorgan involvement in previously healthy per-
sons using e-cigarettes. We agree that definitive 
exclusion of an infectious cause is critical in such 
outbreaks. However, the rates of key microbiolog-
ic investigations undertaken by the primary clin-
ical teams were too low. These included human 
immunodeficiency virus testing in 27 of 53 cases, 
respiratory virus and atypical bacteria polymerase-
chain-reaction (PCR) panels in 34 of 53, sputum 
cultures in 24 of 53 (it was not stated whether 
induced sputum sampling was pursued), and BAL-
fluid culture in 18 of 24 case patients undergoing 
BAL. Greater emphasis must be placed on thorough 
microbiologic evaluation in challenging cases of 
suspected infection. Furthermore, we suggest that 
in an outbreak scenario, application of nonroutine 
bacterial PCR testing (including for legionella spe-
cies) is warranted.1 Emerging methods such as 
metagenomics should also be considered to in-
crease diagnostic yield and ensure that a previously 
unknown pathogen is not missed.2-4 Early detec-
tion of an emerging or reemerging infection will 
require a more meticulous approach to infectious 
disease diagnostics.
Clark D. Russell, M.B., Ch.B.
University of Edinburgh 
Edinburgh, United Kingdom 
clark . russell@ ed . ac . uk
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University of St. Andrews 
St. Andrews, United Kingdom
No potential conflict of interest relevant to this letter was re-
ported.
This letter was published on November 20, 2019, at NEJM.org.
1. Gadsby NJ, Helgason KO, Dickson EM, et al. Molecular diag-
nosis of Legionella infections — clinical utility of front-line 
screening as part of a pneumonia diagnostic algorithm. J Infect 
2016; 72: 161-70.
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF EDINBURGH LIB on November 28, 2019. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF EDINBURGH LIB on November 28, 2019. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
Correspondence
n engl j med nejm.org 3
2. Miller RR, Montoya V, Gardy JL, Patrick DM, Tang P. Metage-
nomics for pathogen detection in public health. Genome Med 
2013; 5(9): 81.
3. Charalampous T, Kay GL, Richardson H, et al. Nanopore 
metagenomics enables rapid clinical diagnosis of bacterial low-
er respiratory infection. Nat Biotechnol 2019; 37: 783-92.
4. Wilson MR, Sample HA, Zorn KC, et al. Clinical metage-
nomic sequencing for diagnosis of meningitis and encephalitis. 
N Engl J Med 2019; 380: 2327-40.
DOI: 10.1056/NEJMc1915111
The authors reply: Diaz et al. highlight the po-
tential for severe airway reactivity and periopera-
tive challenges when performing bronchoscopy 
and BAL in patients with EVALI, and Russell and 
Cevik stress the importance of ruling out infec-
tious causes in these patients. These two points 
reflect the complexities of evaluating patients with 
EVALI and managing their care. Recent Centers 
for Disease Control and Prevention clinical guid-
ance emphasizes that the decision to perform a 
bronchoscopy and BAL should be made on a 
case-by-case basis and in consultation with pul-
monary specialists.1 Many patients with EVALI have 
required intubation and mechanical ventilation, 
and consultation with critical care specialists is 
also recommended.
Many infectious and noninfectious illnesses 
can manifest with respiratory, constitutional, and 
gastrointestinal symptoms. Especially as the in-
fluenza season begins, clinicians must rely on a 
thorough initial evaluation, including history tak-
ing with respect to substance use, travel, vacci-
nations, and sick contacts. Laboratory testing 
should be performed to evaluate for multiple 
causes, including common infections. A chest 
radiograph should be obtained for patients with 
suspected EVALI, and a chest computed tomo-
graphic scan should be considered if the chest 
radiograph is normal.1 Clinicians should strong-
ly consider admitting patients with potential 
EVALI, especially if they have respiratory distress, 
coexisting conditions, or decreased (<95%) oxy-
gen saturation.1
If EVALI is suspected, a comprehensive assess-
ment of e-cigarette, or vaping, product use habits 
should be conducted, including information on 
types of products and substances (e.g., tetrahydro-
cannabinol [THC] and nicotine) used, frequency of 
use, and where products were obtained. A recent 
study in Illinois showed that patients 18 to 44 
years of age with EVALI had higher odds of obtain-
ing products from informal sources and reporting 
exclusive and frequent use of THC-containing 
e-cigarette, or vaping, products than persons 
without EVALI who reported using these products.2
As of November 13, 2019, at total of 2172 
EVALI cases and 42 deaths have been reported in 
49 states, the District of Columbia, and the U.S. 
Virgin Islands. Although vitamin E acetate was 
recently identified in a preliminary analysis of 
BAL specimens,3 evidence is not yet sufficient to 
rule out the contribution of other toxicants. This 
investigation remains ongoing, and vigilant clin-
ical evaluation, diagnosis, and management of 
the care of patients with EVALI are critical.
Jennifer E. Layden, M.D., Ph.D.
Illinois Department of Public Health 
Chicago, IL 
jennifer . layden@ illinois . gov
Brian A. King, Ph.D., M.P.H.
Centers for Disease Control and Prevention 
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Jonathan Meiman, M.D.
Wisconsin Department of Health Services 
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